Jade Biosciences (JBIO) EBT (2020 - 2026)

Jade Biosciences (JBIO) has 7 years of EBT data on file, last reported at -$40.4 million in Q1 2026.

• For the quarter ending Q1 2026, EBT fell 5.72% year-over-year to -$40.4 million; the trailing twelve-month figure through Mar 2026 stood at -$123.3 million (down 22.95% YoY), and the FY2025 full-year result was $236000.0, up 100.34% from the prior year.
• EBT for Q1 2026 stood at -$40.4 million, down from -$31.9 million in the prior quarter.
• Across five years, EBT topped out at $45.2 million in Q4 2023 and bottomed at -$47.0 million in Q4 2024.
• The 5-year median for EBT is -$19.0 million (2023), against an average of -$15.6 million.
• The widest annual swing landed in 2022, when EBT jumped 434.4%; it then slumped 4254.03% in 2025.
• A 5-year view of EBT shows it stood at $27.5 million in 2022, then jumped by 64.51% to $45.2 million in 2023, then slumped by 203.89% to -$47.0 million in 2024, then jumped by 32.11% to -$31.9 million in 2025, then declined by 26.52% to -$40.4 million in 2026.
• The last three EBT figures came in at -$40.4 million (Q1 2026), -$31.9 million (Q4 2025), and -$25.1 million (Q3 2025), per Business Quant data.

Peer Comparison